Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C] TAK-831 in Male Healthy Participants

The purpose of this study is to determine ABA of TAK-831 following a single microdose intravenous administration of 50 microgram (mcg) (approximately 1 microcurie [mcCi]) [14C] TAK-831 and a single oral administration of 500 milligram (mg) TAK-831 tablets in Period 1, and to assess the mass balance, characterize the PK of TAK-831 in plasma and urine, and total radioactivity concentration equivalents in plasma and whole blood following a single oral suspension dose of 500 mg (approximately 100 mcCi) [14C]TAK-831 in Period 2.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - TAK-831 Oral Tablet

TAK-831 tablet.

Drug - [14C]TAK-831 Intravenous Infusion

[14C]TAK-831 intravenous infusion.

Drug - [14C]TAK-831 Oral Suspension

[14C]TAK-831 oral suspension.

Additional Information

Official Study Title

A Phase 1 Study to Assess Absolute Bioavailability of TAK-831 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Subjects

Clinical Trial ID

NCT04234672

ParticipAid ID

eXDyle